zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2022 / Oneness Biotech Co., Ltd. receives a Canadian patent on FB704A, an anti-IL6 fully-human antibody new drug.

Oneness Biotech Co., Ltd. receives a Canadian patent on FB704A, an anti-IL6 fully-human antibody new drug.

2022-01-19

Published Date:2022-01-19

Original Link:https://www.onenessbio.com/en/news_detail137_4.htm

No 1 Date of announcement 2022/01/19 Time of announcement 17:09:48
Subject Oneness Biotech Co., Ltd. receives a Canadian patent on FB704A, an anti-IL6 fully-human antibody new drug.
To which item it meets paragraph 53 Date of events 2022/01/19
Statement
  1. Date of occurrence of the event:2022/01/19
  2. Company name:ONENESS BIOTECH CO., LTD.
  3. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
  4. Reciprocal shareholding ratios:NA
  5. Cause of occurrence:
    The Company has been informed by the patent agency that the FB704A, an anti-IL6 fully-human antibody new drug has been granted a Canadian patent titled ”ANTIBODIES TO INTERLEUKIN-6 AND USES THEREOF”under the patent number 2,889,181.
  6. Countermeasures:None
  7. Any other matters that need to be specified:None